Brief: Zelluna Completes First GMP Batch Of ZI-MA4-1
12/12/2025 12:06
Dec 12 (Reuters) - Zelluna ASA ZLNA.OL: COMPLETES FIRST GMP BATCH OF ZI-MA4-1, A NOVEL TCR-NK CELL THERAPY, TO TREAT PATIENTS IN UPCOMING FIRST-IN-HUMAN TRIAL MATERIAL FOR FIRST-IN-HUMAN CLINICAL TRIAL MARKS MILESTONE ON TRACK TO SUBMIT CTA FOR ZI-MA4-1 IN 2H 2025 Source text: ID:nGNE89JnQm Further company coverage: ZLNA.OL (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Zelluna ASA
See all newsNorway's Zelluna ASA reports Q2 loss
Brief: Zelluna Reports Q2 Total Loss Of NOK 19.7 Million
Brief: Zelluna Says IDMC Recommends Recruitment Of Next Two Patients At First Dose Level
Brief: Zelluna Says First Patient Dosed With Zi-Ma4-1 In Zima-101 Phase 1 Trial
Brief: Zelluna Wins NOK 16 Mln Research Council Of Norway Grant